Contact Us
 • 
Home
Search 

About Us

LEDDU focuses the required knowledge and talent for the development of early phase studies in areas including small molecule inhibitors, immunotherapy, and gene therapy and other novel agents, biomarker development and molecular analysis of clinical samples.

To support early phase clinical trials and translational research the LEDDU is led by Professor Daniel Palmer (Chair Medical Oncology) and Dr Syed Hussain (Clinical Senior Lecturer, Medical Oncology). Leadership is underpinned by collaborative working between Clatterbridge Cancer Centre Foundation Trust (CCC) the University of Liverpool, Royal Liverpool and Broadgreen University Hospitals (RLUH) and other stakeholders in Liverpool Health Partners. LEDDU is in turn part of the Liverpool Cancer Research UK Centre and governance and Good Clinical Practice Laboratories (GCLP) and GCLP Biobanking are all underpinned by the Cancer Research UK Liverpool Cancer Trials Unit (LCTU). This is one of only six Cancer Research UK CTUs and is one of the largest of the fully Registered UKCRC CTUs.

The strategy of Liverpool Cancer Research UK Centre is focussed on integrating cancer research, education and clinical service the key partners include:

-     The University of Liverpool

-     The Clatterbridge Cancer Centre

-     The Royal Liverpool University Hospital

-     Liverpool Health Partners

-     NHS Commissioners

-     Merseyside and Cheshire Cancer Network

-     Merseyside and Cheshire Cancer Research Network

-     North West Cancer Research

-     Clatterbridge Cancer Charity

-     The Liverpool City Council

-     Cancer Research UK

 

LEDDU is an integral component of the research capabilities of the Department of Cancer and Molecular Medicine, University Of Liverpool. The development of LEDDU forms part if the Department’s strategy for growth over the forthcoming years, to produce an integrated translational research program, in which basic research identifies new drug targets which then can be tested in clinical trials. Drug development, biomarker and drug resistance studies carried out as part of these trials can then indicated new areas for both clinical and basic research.